The latest Business updates from the science industry


by Heather Hobbs


Markes International Becomes Licensed World Commercial Supplier of Thin-film Solid-phase Microextraction


analytes from solids and liquids, using immersive or headspace techniques, often with higher sensitivity. It’s also very fl exible and therefore robust for use in harsh environments.


Both SPME and TF-SPME were invented by Professor Janusz Pawliszyn from the University of Waterloo – a founder and board member of JP Scientifi c Ltd. Professor Pawliszyn said: “JP Scientifi c’s mission is to facilitate the implementation of green analytical chemistry into practice through partners such as Markes, who are as keen as we are to develop sampling devices, apparatus and protocols which make sensitive and environmentally friendly analytical approaches possible.


Professor Pawliszyn, JP Scientifi c Ltd.


Markes International Ltd has entered into a licensing and supply agreement with JP Scientifi c Ltd, producer and patent holder of thin- fi lm solid-phase microextraction (TF-SPME), allowing Markes to supply the novel sampling device worldwide for a wide range of applications.


TF-SPME is a sampling technique that uses carbon mesh sheets impregnated with sorbent phase(s). It is similar to the well-known technique of SPME, but relative to fi bre SPME, both the volume of extraction phase and the surface area to volume ratio are signifi cantly larger due to its fl at planar geometry and sorbent phase concentration.


Like SPME it can be used to extract volatile and semi-volatile


“Through our licensing and supply agreement with Markes, researchers around the globe will have a reliable and consistent source of supply of TF-SPME. This is a landmark moment in analytical science, as it will meet the growing need for more sensitive and yet robust sampling.”


Andy Hardwick, Commercial Director of Markes’ parent company, Schauenburg Analytics Ltd agreed, adding: “Through this agreement Markes will be able to offer clients a hard-to-rival level of expertise and support, instrumentation, accessories and consumables to enhance the analytical capability of GC–MS. The improved sensitivity in the sampling of volatile and semi-volatile organic compounds afforded by TF-SPME will be particularly helpful in water quality, environmental, forensic, food, fl avour and fragrance applications.”


Hardwick continued: “Markes’ and The University of Waterloo’s collaboration has in many ways been facilitated through the


University’s long-standing relationship with Markes’ sister company, SepSolve Analytical Ltd. In fact, SepSolve very recently opened its newest base in Waterloo to be nearer to the University and further develop this alliance.


“Both Markes and SepSolve are part of Schauenburg Analytics Ltd; Markes manufactures and sells instrumentation for sample preparation and concentration, including thermal desorption, SPME, headspace and HiSorb™ high-capacity sorptive extraction. It also supplies a comprehensive range of instruments, sampling equipment and supplies that enhance the analytical capability of GC–MS.


“SepSolve provides tailored product and application packages for the analytical workfl ow process from sampling through to detection, including GC×GC and time-of-fl ight mass spectrometry, all brought together with powerful software in order to extract maximum analytical data and deliver faster throughput.


“Together, the two companies form a network of Schauenburg Analytics technical centres around the world, serving the needs of customers not just through the provision of instrumentation and equipment, but also through their combined knowledge base and partnerships developed with academic institutions.


Markes will be launching its TF-SPME fi bres and starter kits for its thermal desorption instruments in early 2020. The company will also be featuring the new range at Pittcon 2020 and Analytica Germany 2020.


More information online: ilmt.co/PL/E0jw 50996pr@reply-direct.com


Funding to Underpin Further Advances in Cancer Therapies


aminopeptidase 2 (ERAP2), following positive signals of its potential and also be used to continue to drive the lead endoplasmic reticulum aminopeptidase 1 (ERAP1) modulator program. Both approaches are aimed at directly altering tumour cells, illuminating them for attack and destruction by the immune system. The goal is to exploit this increased tumour visibility in monotherapy and to extend the therapeutic benefi t of already approved immunotherapies to many more cancers.


“We are delighted to have the continued support of Andera and Canaan.” said Peter Joyce, Chief Executive Offi cer and Co-Founder. “The fi nancing refl ects growing potential in both our ERAP1 and ERAP2 approaches. We continue to see momentum, both in our own work and in the broader scientifi c community. These funds will allow us to further capitalise on this opportunity and expand our leadership position in the discovery and development of both ERAP1 and ERAP2 modulators.”


Peter Joyce


Biotech Grey Wolf Therapeutics, focused on developing therapies for immuno-oncology (IO), has completed a £2.5 million ($3.3 million) Series A2 fi nancing round with existing leading international healthcare investors Andera Partners and Canaan.


The new funding – all from existing investors – will accelerate development of therapies targeting endoplasmic reticulum


“We have continued to generate data showing that modulation of both ERAP pathways drives change to the cancer-related antigen repertoire,” said Tom McCarthy, Executive Chairman and Co- Founder of Grey Wolf Therapeutics. “Data clearly demonstrates that modulation of ERAP2 drives an altogether different change to the antigen repertoire, when compared with ERAP1 modulation, due to ERAP2’s clearly differentiated peptide substrate specifi cities. With this investment and the prior knowledge base within Grey Wolf we will be able to accelerate the ERAP2 program quickly.”


51129pr@reply-direct.com


Andrew Alliance to be Acquired by Waters


Waters Corporation have announced that it has entered into a defi nitive agreement to acquire Andrew Alliance, an innovator in specialty laboratory automation technology, including software and robotics. Andrew Alliance’s cloud-native software platform and modern interface dramatically improves the use of automation technology, enabling more scientists to realise the advantages of repeatability and performance for both routine and complex laboratory workfl ows.


“The acquisition of Andrew Alliance broadens our technology portfolio to include advanced robotics and software that will positively impact our customers’ workfl ows across pharmaceuticals, life sciences and materials science markets,” commented Chris O’Connell, Chairman and Chief Executive Offi cer of Waters Corporation. “This move also demonstrates Waters’ commitment to deploy capital to growth- oriented acquisitions that reinforce our specialty strategy and enhance our core business.”


Andrew Alliance has approximately 40 employees in Switzerland, France and the United States.


“We are thrilled to join the Waters family,” commented Piero Zucchelli, Chief Executive Offi cer of Andrew Alliance. “We have found the right partner to bring our vision of connected laboratories to life. Waters’ combination of instruments and chemistries will help us accelerate the delivery of our innovative software and hardware technologies to customers as mass spectrometry increasingly moves into the hands of more and more users.”


51137pr@reply-direct.com


Page 1  |  Page 2  |  Page 3  |  Page 4  |  Page 5  |  Page 6  |  Page 7  |  Page 8  |  Page 9  |  Page 10  |  Page 11  |  Page 12  |  Page 13  |  Page 14  |  Page 15  |  Page 16  |  Page 17  |  Page 18  |  Page 19  |  Page 20  |  Page 21  |  Page 22  |  Page 23  |  Page 24  |  Page 25  |  Page 26  |  Page 27  |  Page 28  |  Page 29  |  Page 30  |  Page 31  |  Page 32  |  Page 33  |  Page 34  |  Page 35  |  Page 36  |  Page 37  |  Page 38  |  Page 39  |  Page 40  |  Page 41  |  Page 42  |  Page 43  |  Page 44  |  Page 45  |  Page 46  |  Page 47  |  Page 48  |  Page 49  |  Page 50  |  Page 51  |  Page 52  |  Page 53  |  Page 54  |  Page 55  |  Page 56  |  Page 57  |  Page 58  |  Page 59  |  Page 60  |  Page 61  |  Page 62  |  Page 63  |  Page 64  |  Page 65  |  Page 66  |  Page 67  |  Page 68  |  Page 69  |  Page 70  |  Page 71  |  Page 72  |  Page 73  |  Page 74  |  Page 75  |  Page 76  |  Page 77  |  Page 78  |  Page 79  |  Page 80  |  Page 81  |  Page 82  |  Page 83  |  Page 84  |  Page 85  |  Page 86  |  Page 87  |  Page 88